[Previous Months][Date Index][Thread Index][Join - Register][Login]
[Message Prev][Message Next][Thread Prev][Thread Next]
[IP] Only Small Differences Between Insulin Lispro and Aspart
Only Small Differences Between Insulin Lispro and Aspart
Two rapid-acting insulin analogs, lispro and aspart, were compared in this
after subcutaneous injection in patients with type 1 diabetes.
Fourteen patients with type 1 diabetes were recruited for the study. Only
patients had measurable C-peptide levels. All patients were on
multiple-injection therapy with a breakfast insulin dose of 11.1 1 0.7 U
614) and no intermediate-acting insulin in the morning.
The study was designed as a single blind randomized crossover study. On the
first day, seven patients were randomized to insulin lispro (Humalog, U-100;
Lilly, Indianapolis, IN), and the other seven were randomized to insulin
(NovoRapid, U-100; Novo-Nordisk, Bagsveard, Denmark). On the second study
(521 days later), the patients received the alternative insulin analog. The
patients continued their usual insulin treatment between the study days.
The impression from previous studies is that insulin aspart gives a somewhat
broader peak than lispro. We found a significantly more rapid lowering of
free insulin concentration to 50% of the peak concentration with lispro. The
plasma profile of free insulin obtained is dependent on the rate of
of insulin from subcutaneous tissue and the elimination of insulin from the
Because the metabolic clearance of insulin analogs is predominately receptor
mediated and because lispro and aspart have about the same affinity for the
insulin receptor, it seems probable that they will have about the same
rate and that the lowering of free insulin after the peak is mainly due to
rate of absorption.
>From the clinical point of view, the most important observation is that
analogs are absorbed much faster than human insulin after subcutaneous
injection, with higher insulin peaks and shorter duration of action. Because
high postprandial glucose and lipid levels have been emphasized as risk
especially in type 2 diabetes, this may be of importance. In this respect,
relatively rapid rise of free insulin levels after injection of insulin
might be an advantage.
The slightly slower decrease of free insulin concentrations after the
peak of insulin aspart might influence the need for daytime basal insulin
the need for a snack between the main meals of certain patients.
We previously found no difference in IGFBP-1 concentrations when using human
regular insulin or insulin lispro, and in this study there was no difference
between insulin aspart and lispro.
The main finding of our study is that the free insulin profiles of aspart
lispro resemble each other, but insulin lispro shows a more rapid uptake,
reaches the maximum peak concentration earlier, and shows a more rapid
than insulin aspart. We believe this finding may be of clinical importance.
Diabetes Care 24:1120-1121, 2001
Get your FREE download of MSN Explorer at http://explorer.msn.com
for HELP or to subscribe/unsubscribe, contact: HELP@insulin-pumpers.org
send a DONATION http://www.Insulin-Pumpers.org/donate.shtml